Results 331 to 340 of about 752,578 (365)
Some of the next articles are maybe not open access.
Pathophysiology of Haemostasis and Thrombosis, 1994
Thrombosis is the most frequent complication and the second cause of death in patients with overt malignant disease. Increasing evidence suggests that thrombotic episodes may also precede the diagnosis of cancer by months or years thus representing a potential marker for occult malignancy.
openaire +3 more sources
Thrombosis is the most frequent complication and the second cause of death in patients with overt malignant disease. Increasing evidence suggests that thrombotic episodes may also precede the diagnosis of cancer by months or years thus representing a potential marker for occult malignancy.
openaire +3 more sources
2001
Complications of macrovascular disease are responsible for 50% of the deaths in patients with type 2 diabetes mellitus (DM), 27% of the deaths in patients with type 1 diabetes for 35 years or less, and 67% of the deaths in patients with type 1 diabetes for 40 years or more (1,2). The rapid progression of macroangiopathy in patients with type 2 diabetes
Burton E. Sobel, David J. Schneider
openaire +2 more sources
Complications of macrovascular disease are responsible for 50% of the deaths in patients with type 2 diabetes mellitus (DM), 27% of the deaths in patients with type 1 diabetes for 35 years or less, and 67% of the deaths in patients with type 1 diabetes for 40 years or more (1,2). The rapid progression of macroangiopathy in patients with type 2 diabetes
Burton E. Sobel, David J. Schneider
openaire +2 more sources
The Hematology Journal, 2004
Venous thromboembolism is a common problem in cancer patients. It complicates both the surgical management of those with cancer and has been associated with varying risk for the development of clinical thromboembolism in patients receiving chemotherapy.
openaire +3 more sources
Venous thromboembolism is a common problem in cancer patients. It complicates both the surgical management of those with cancer and has been associated with varying risk for the development of clinical thromboembolism in patients receiving chemotherapy.
openaire +3 more sources
Pharmacogenomics in Thrombosis
2010Inherited or acquired genetic abnormalities play a major role in thromboembolic complications. The goal of pharmacogenomics is to tailor medications to an individual's genetic makeup in order to improve the benefit-to-risk ratio. Significant findings have been documented showing the effect of certain genetic variations (e.g., in CYP2C9 and VKORC1) on ...
openaire +3 more sources
Journal of the American Medical Association (JAMA), 2005
I. Iakovou +15 more
semanticscholar +1 more source
I. Iakovou +15 more
semanticscholar +1 more source
Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis
Arteriosclerosis, Thrombosis and Vascular Biology, 2018S. Grover, N. Mackman
semanticscholar +1 more source